OptiBiotix Health’s Stephen O’Hara discusses the key points from their half-year report in this exclusive interview with DirectorsTalk
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the release of it’s 6 month interim’s. Stephen talks about the IP, scientific, and commercial aspects of the results.
Optibiotix Health Plc (LON:OPTI) is the topic of conversation with Hybridan researcher and corporate broker Nathan Derren. The company has made great progress since its IPO and Nathan explains what
OptiBiotix Health’s Stephen O’Hara discusses their new strategy and what this will mean for investors in this exclusive interview with DirectorsTalk
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about it’s new strategy, the thinking behind this, what it means for shareholders and when we can expect to see
Rose Petroleum Plc (LON:ROSE) CEO Matthew Idiens caught up with DirectorsTalk to talk about key areas of focus now for the company, why they view “the future with optimism”, how
OptiBiotix Health’s Stephen O’Hara discusses their new development agreement with Royal DSM in this exclusive interview with DirectorsTalk
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara caught up with DirectorsTalk to talk about the JV with DSM. Stephen expands on the agreement details, explains the types of products involved
OptiBioTix Health’s Stephen O’Hara discusses the further fund raise of £2.2 million, what these funds will be used for and the opportunities in skin health in this exclusive interview with DirectorsTalk
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara chats with DirectorsTalk about the further fund raise and how the money will be used. Stephen highlights some exciting opportunities in the healthcare
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
